MONTVALE, N.J., March 31 Synvista Therapeutics,Inc. (Amex: SYI) announces data from a study of diabetic mice with theHaptoglobin 2-2 genotype that show impairment in the clearance of theHaptoglobin (Hp)-Hemoglobin (Hb) complex may result in a modification ofhigh-density lipoprotein (HDL) structure and defective reverse cholesteroltransport. These findings, which were presented today at the 57th AnnualScientific Sessions of the American College of Cardiology in Chicago, suggestthe value of Haptoglobin testing in people with diabetes in order to ensuremore successful treatment in the prevention of cardiovascular events (such asheart attack and stroke).
"These data from a validated animal model support our belief thatHaptoglobin testing may help physicians tailor optimal therapy for patientswith diabetes who may be at risk for cardiovascular events. The transport ofcholesterol out of atherosclerotic plaque may be an important mechanism ofstroke and heart attack prevention. Characterizing the functional impairmentof HDL may help us understand how to intervene in Hp2-2 diabetic patients,"said Noah Berkowitz, M.D., Ph.D., President and Chief Executive Officer ofSynvista Therapeutics, which is developing a diagnostic product to identifyHaptoglobin types. "As with previous studies of diabetic patients exhibitingmarkedly elevated cardiovascular risk, we believe that these findings supportthe notion of testing for Haptoglobin and treating the appropriate diabeticpatients (Hp2-2) with vitamin E."
In the study, researchers assessed clearance of Hb by Hp in diabetic micethat were also tested for Hp type. The study showed that in these mice, thecombination of diabetes and the Hp2-2 genotype was associated with atwo-to-three-fold increase in the half-life of the Hp-Hb complex compared toother Hp types. Further, a greater than 10-fold increase was found in theassociation of Hp-2-Hb and HDL in these mice. The study also demonstratedthat vitamin E supplementation prevented the impairment of reverse cholesteroltransport in diabetic mice with the Hp2-2 genotype.
About Haptoglobin 2-2
The Hp protein is polymorphic in humans, occurring with two alleles, 1 and2, existing at the Hp genetic locus. Three phenotypes linked to the threegenotypes, Hp 1-1, Hp 1-2 and Hp 2-2, can be identified using an ELISA assay.In multiple independent prospective longitudinal studies of more than 20,000individuals, it has been established that the Haptoglobin genotype is anindependent risk factor for cardiovascular disease, with a specificrelationship to patients with diabetes mellitus. After accounting forconventional cardiovascular risk factors and diabetes characteristics in thesestudies, research has demonstrated that there is a 2-5 fold increased risk ofcardiovascular disease in people with both diabetes and the Hp 2-2 genotype(approximately 40 percent of all diabetes patients).
About Synvista Therapeutics
Synvista Therapeutics is a biopharmaceutical company developing drugs totreat and prevent cardiovascular disease and nephropathy in people withdiabetes. The Company believes it has identified several product candidatesthat represent novel approaches to some of the largest pharmaceutical markets.The Company's portfolio includes orally bioavailable, organoselenium mimics ofglutathione peroxidase. These compounds metabolize lipid peroxides and havethe potential to limit myocardial damage subsequent to a myocardialinfarction. The Company is developing a clinical diagnostic test, based oncardiovascular risk assessment, using Haptoglobin characterization, toidentify patients at high risk for cardiovascular complications of diabetes.
Synvista Therapeutics also is developing alagebrium, a proposed breaker ofAGEs for the treatment of diastolic heart failure. This disease represents arapidly growing market of unmet medical need, particularly co